PhaseRx, Inc.

PZRXQ

US71723F1030

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 08:12:58 21/09/2023 pm IST			5-day change	1st Jan Change
0.0002 ^USD	-.--%		-.--%	-.--%

2019	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
2018	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index

December 13, 2017 at 10:30 am IST

Latest news about PhaseRx, Inc.

Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	31/19/31	CI
PhaseRx, Inc. Bankruptcy Case Dismissed	23/18/23	CI
Motion for Case Dismissal Filed for PhaseRx, Inc.	07/18/07	CI
Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	20/18/20	CI
PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	02/18/02	CI
Motion for Asset Sale Approved for PhaseRx, Inc.	01/18/01	CI
Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	01/18/01	CI
Bidding Procedure Approved for PhaseRx, Inc.	27/17/27	CI
PhaseRx Considers Multiple Alternatives	14/17/14	CI
PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	13/17/13	CI
PhaseRx, Inc. Filed for Bankruptcy	11/17/11	CI
Motion for Asset Sale Filed by PhaseRx, Inc.	11/17/11	CI
PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	09/17/09	CI
Phaserx, Inc. Announces Termination of Michael Houston as Chief Scientific Officer	13/17/13	CI
PhaseRx, Inc. Announces Reduction of Workforce by 10 Employees	13/17/13	CI
PhaseRx Seeks Corporate Restructuring And Alternatives	13/17/13	CI
Phaserx To Cut Half Its Workforce, Looks Into Potential Merger	13/17/13	CI
PhaseRx, Inc. Appoints Robert W. Overell as Principal Accounting Officer	26/17/26	CI
PhaseRx, Inc. Announces Resignation of Shing-Yin Tsui as Senior Vice President, Finance, Secretary and Principal Accounting Officer, Effective as of September 15, 2017	09/17/09	CI
Phaserx Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2017	10/17/10	CI
PhaseRx, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	12/17/12	CI
PhaseRx, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	27/17/27	CI
Certain Preferred Stock of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	14/16/14	CI
Certain Warrants of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	14/16/14	CI
Certain Stock Options of PhaseRx, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2016.	14/16/14	CI

Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHASERX, INC.	-.--%	2.34K
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+0.93%	22.28B
BIONTECH SE	-11.90%	22.41B
GENMAB A/S	-5.99%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs

PhaseRx, Inc.

Equities

PZRXQ

US71723F1030

Biotechnology & Medical Research

PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index

Latest news about PhaseRx, Inc.

Chart PhaseRx, Inc.

Company Profile

Sector Bio Therapeutic Drugs